Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04283097
Other study ID # KPG-818-HEM-101
Secondary ID
Status Recruiting
Phase Phase 1
First received
Last updated
Start date September 13, 2021
Est. completion date May 14, 2025

Study information

Verified date March 2024
Source Kangpu Biopharmaceuticals, Ltd.
Contact Yao Wang, MD
Phone +19738738678
Email yao.wang@kangpugroup.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This is a phase 1, multicenter, open-label, multiple-ascending dose study to evaluate the safety, pharmacokinetics and clinical activity of KPG-818 in subjects with hematological malignancies. Approximately 30 patients will be enrolled for dose escalation of 4 dose levels. Indication: Hematological malignancies (multiple myeloma [MM], mantle cell lymphoma [MCL], diffuse large B-cell lymphoma [DLBCL], adult T-cell leukemia-lymphoma [ATL], and indolent non Hodgkin lymphomas such as follicular lymphoma [FL] and chronic lymphocytic leukemia [CLL]/small lymphocytic lymphoma [SLL]).


Description:

This will be a dose escalation study in subjects with selected hematological malignancies. KPG-818 will be used in combination with dexamethasone in subjects with MM, and as monotherapy for other selected hematological malignancies. Each dose of KPG-818 will be administered orally until the completion of treatment cycles, or progressive disease (PD), unacceptable toxicity, the subject withdraws, or any other study withdrawal criterion is met. The highest dose level which may be tested is 5 mg KPG-818 and dose levels 2, 3, 4, and 5 mg and/or intermediate dosing or alternative dosing schedule may be explored. Each dose level (1-4) will be tested using the standard 3+3 design. DLT will be assessed during the DLT evaluation period (Cycle 1) and the treatment of study is divided into 6 cycles.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date May 14, 2025
Est. primary completion date October 1, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. = 18 years of age 2. Willing and able to provide written consent. 3. Willing and able to adhere to the study visit schedule and other protocol requirements. 4. Hematocytological or pathological diagnosis of MM, MCL, DLBCL, ATL, indolent lymphoma, such as FL and CLL/SLL, etc. 5. Subjects who have relapsed from or are refractory to MM, MCL, DLBCL, ATL, indolent lymphoma, such as FL and CLL/SLL. 6. Have measurable or assessable disease. 7. Meet the laboratory requirements: 8. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2. 9. Males and females of childbearing potential must agree to use at least two methods of contraception and continue until 3 months after the completion of study treatment. Exclusion Criteria: 1. Has any significant medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from participating in the study. 2. Currently enrolled in another clinical study, except observational studies. 3. Has known active central nervous system metastases and/or lymphomatous meningitis. 4. Persisting toxicities related to prior anticancer treatment > Grade 1. 5. Major surgery or significant traumatic injury within 6 weeks prior to Screening or planned major surgery during the study period. 6. Received live attenuated vaccine within 4 weeks of first dose. 7. Subjects with gastrointestinal disease that may significantly alter the absorption of the study drug. 8. Subjects with a plasma cell leukemia. 9. Subjects with prior history of malignancies, other than MM, lymphoma, or CLL/SLL, unless the subject has been free of the disease for = 5 years. 10. Has a history of anaphylaxis or hypersensitivity to thalidomide, lenalidomide, or pomalidomide. 11. Has known or suspected hypersensitivity to the excipients contained in the formulation of investigational product (IP). 12. Has been treated with an investigational agent (i.e., an agent not commercially available) within 28 days of initiating IP. 13. Prior treatment of any inhibitors of PD-1 or PD-L1 within 3 months prior to initiating IP. 14. Has any one of the following: - Clinically significant abnormal ECG finding at Screening. - Congestive heart failure. - Myocardial infarction within 12 months prior to initiating IP. - Unstable or poorly controlled angina pectoris, including the Prinzmetal variant of angina pectoris. - Peripheral neuropathy = Grade 2. - Subject has taken a strong inhibitor or inducer of CYP3A4/5 including grapefruit, St. John's Wort or related products within 2 weeks prior to dosing and during the course of study. 15. Has current or prior use of immunosuppressive medication within 14 days prior initiating IP. 16. Subject known to test positive for human immunodeficiency virus, active hepatitis B, or active hepatitis C. 17. Subject is unable or unwilling to undergo protocol required thromboembolism prophylaxis. 18. Subject is a female who is pregnant, nursing, or breastfeeding.

Study Design


Intervention

Drug:
KPG-818
The 4 planned dose level (cohorts) of KPG-818 will be explored: 2, 3, 4 and 5mg. Each dose of KPG-818 will be administered orally with approximately 240 ml of water daily, and used as a single agent in subjects with selected hematological malignancies (or in combination with dexamethasone weekly for MM), according to specific dosing schedule in each treatment cycle until disease progression, unacceptable toxicity, the subject withdraws, or any other study withdrawal criterion is met. The treatment of study is divided into 6 cycles.

Locations

Country Name City State
United States Henry Ford Health System - Hemophilia and Thrombosis Treatment Center Detroit Michigan
United States Duke University Health System - Duke Endoscopy - Duke Clinic 2H Durham North Carolina
United States Laguna Clinical Research Associates Laredo Texas
United States Norton Cancer Institute Louisville Kentucky
United States Medical College of Wisconsin Milwaukee Wisconsin
United States Mohamad Medical Cherry Morristown New Jersey
United States UPMC CancerCenter Pittsburgh Pennsylvania
United States BRCR Global - USA Plantation Florida
United States Providence Portland Medical Center Portland Oregon
United States UC Davis Comprehensive Cancer Center Sacramento California

Sponsors (1)

Lead Sponsor Collaborator
Kangpu Biopharmaceuticals, Ltd.

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other Biomarkers of KPG-818 Aiolos and Ikaros in peripheral blood mononuclear cell (PBMC) Up to 6 months of treatment
Primary Treatment-Emergent Adverse Events [Safety and Tolerability] Number of Treatment-Emergent Adverse Events(TEAE), serious adverse events (SAEs), dose-limiting toxicities (DLTs), and changes from baseline in laboratory parameters, vital signs, and ECG. Up to 6 months of treatment
Primary Recommended Phase 2 Dose (RP2D) Maximum tolerated dose defined as the highest dose level at which 33% or less subjects experience DLT as defined by the protocol. Up to 4 weeks of treatment
Secondary PK profile of KPG-818: maximum observed plasma concentration (Cmax). Up to 4 weeks of treatment
Secondary PK profile of KPG-818: time of the maximum observed plasma concentration (Tmax) Up to 4 weeks of treatment
Secondary PK profile of KPG-818: area under the plasma concentration-time profile (AUC) from time zero to the last quantifiable concentration (AUC0-t). Up to 4 weeks of treatment
Secondary PK profile of KPG-818: AUC from time zero extrapolated to infinity (AUC0-8). Up to 4 weeks of treatment
Secondary PK profile of KPG-818: AUC within a dosing interval (AUC0-t). Up to 4 weeks of treatment
Secondary PK profile of KPG-818: apparent total plasma clearance (CL/F). Up to 4 weeks of treatment
Secondary PK profile of KPG-818: apparent total plasma clearance at steady-state (CLss/F). Up to 4 weeks of treatment
Secondary PK profile of KPG-818: apparent volume of distribution (Vz/F) Up to 4 weeks of treatment
Secondary PK profile of KPG-818: apparent volume of distribution at steady-state (Vss). Up to 4 weeks of treatment
Secondary PK profile of KPG-818: apparent plasma terminal elimination. half-life (t1/2) Up to 4 weeks of treatment
Secondary Assessment of clinical activity: objective response rate (ORR). Responses are evaluated based on International Myeloma Working Group (IMWG) Uniform Response Criteria (for MM), Lugano Classification (for lymphoma), International Workshop Group on CLL (iwCLL) Response Criteria, and according to the 'Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma' (for ATL). Up to 6 months of treatment
Secondary Assessment of clinical activity: disease control rate (DCR). Responses are evaluated based on International Myeloma Working Group (IMWG) Uniform Response Criteria (for MM), Lugano Classification (for lymphoma), International Workshop Group on CLL (iwCLL) Response Criteria, and according to the 'Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma' (for ATL). Up to 6 months of treatment
Secondary Assessment of clinical activity: time to response, duration of response. Responses are evaluated based on International Myeloma Working Group (IMWG) Uniform Response Criteria (for MM), Lugano Classification (for lymphoma), International Workshop Group on CLL (iwCLL) Response Criteria, and according to the 'Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma' (for ATL). Up to 6 months of treatment
Secondary Assessment of clinical activity: progression-free survival. Responses are evaluated based on International Myeloma Working Group (IMWG) Uniform Response Criteria (for MM), Lugano Classification (for lymphoma), International Workshop Group on CLL (iwCLL) Response Criteria, and according to the 'Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma' (for ATL). Up to 6 months of treatment
Secondary Assessment of clinical activity: event-free survival (EFS), and transplantation rate (TR). Responses are evaluated based on International Myeloma Working Group (IMWG) Uniform Response Criteria (for MM), Lugano Classification (for lymphoma), International Workshop Group on CLL (iwCLL) Response Criteria, and according to the 'Definition, prognostic factors, treatment, and response criteria of adult T-cell leukemia-lymphoma' (for ATL). Up to 6 months of treatment
See also
  Status Clinical Trial Phase
Terminated NCT03248479 - Magrolimab Monotherapy or Magrolimab in Combination With Azacitidine in Participants With Hematological Malignancies Phase 1
Recruiting NCT05454241 - CD7 CAR-T for Patients With r/r CD7+ Hematologic Malignancies Phase 2
Recruiting NCT06041815 - Correlation Between Gut Microbiota and Clinical Response to CAR-T Treatment for Hematological Malignancies
Active, not recruiting NCT05005442 - A Study of Pembrolizumab/Vibostolimab (MK-7684A) in Relapsed/Refractory Hematological Malignancies (MK-7684A-004, KEYVIBE-004) Phase 2
Recruiting NCT02300571 - Observational Study of the Combination of Post-transplant High Dose Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Acute Graft-versus-Host Disease in Patients Eligible to Allogeneic Hematopoietic Stem Cell Transplant N/A
Active, not recruiting NCT01428973 - Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens Phase 2
Completed NCT01162096 - Reduced Intensity Haploidentical Transplant for Hematological Malignancies Phase 1/Phase 2
Terminated NCT00506948 - Thymoglobulin, Sirolimus and Mycophenolate Mofetil for Prevention of Acute Graft-Versus-Host Disease (GVHD) Phase 2
Completed NCT00379587 - Rituximab for Prevention of Chronic GVHD Phase 1/Phase 2
Active, not recruiting NCT04557098 - A Study of Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma Phase 2
Completed NCT03067155 - CMV Specific T Cell Therapy After Allogeneic Stem Cell Transplantation. Phase 2
Completed NCT01725555 - A Study to Assess the Effect of Food on the Bioavailability of the IGF-1R Inhibitor AXL1717 in Patients With Advanced Malignant Tumors Phase 1
Completed NCT00438178 - Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) for the Treatment of Hematological Malignancies Phase 1
Completed NCT03711604 - Compassionate Use Study of Tenalisib (RP6530) Phase 1/Phase 2
Withdrawn NCT01168882 - Safety and Tolerability of RGB-286638 in Patients With Selected, Relapsed or Refractory Hematological Malignancies Phase 1
Completed NCT01246206 - Tacrolimus and Thymoglobulin, as GvHD Prophylaxis in Patients Undergoing Related Donor HCT Phase 2
Completed NCT01172132 - The Use of Intensive Care in Critically Ill Cancer Haematological Patients: "TRIAL-OH" N/A
Completed NCT00506402 - A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies Phase 1
Active, not recruiting NCT00163644 - RCT to Investigate Whether an Exercise Programme Improves the Physical Performance and QOL After BMT N/A
Completed NCT01063647 - Dose-range Finding Treosulfan-based Conditioning Phase 1/Phase 2